# Colchicine Drug · id `cardio:colchicine` · Cardiovascular Atlas · release `f6f6f1b6f50379ed` (public) > General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations. Browse, condition area: Coronary and vascular disease ## In plain language Colchicine is an old medicine, best known for gout, that has anti-inflammatory effects. In the LoDoCo2 trial, a low daily dose lowered the rate of heart and blood-vessel events in people with chronic coronary disease, though deaths from non-cardiovascular causes were reported at a higher rate with colchicine, with an interval that includes no difference. ## Technical summary RxNorm ingredient 2683. The LoDoCo2 abstract tested 0.5 mg once daily. The registry record of a separate trial, COLCOT (NCT02551094), lists coronary artery disease and myocardial infarction as conditions and was committed as a source; its results are not recorded here. ## Claims, with the population each applies to ## Context: Patients with chronic coronary disease (LoDoCo2) Recipient: Adult; Population: Patients with chronic coronary disease; 5522 were randomised (abstract). The abstract does not give an age range. The trial is registered with the Australian New Zealand Clinical Trials Registry, which was not read.; Care setting: Not stated in the source (abstract only); Geography: Not stated in the source (abstract only); Life stage: Adult patients; no age range is stated in the abstract; Follow-up: Median follow-up 28.6 months (abstract). ### In LoDoCo2, 5522 patients with chronic coronary disease were randomised to colchicine 0.5 mg once daily (2762) or placebo (2760). Over a median of 28.6 months, the primary composite end point occurred in 187 patients (6.8%) on colchicine and 264 (9.6%) on placebo (2.5 against 3.6 events per 100 person-years; hazard ratio 0.69, 95% CI 0.57 to 0.83). The key secondary composite occurred in 115 (4.2%) and 157 (5.7%) (hazard ratio 0.72, 95% CI 0.57 to 0.92). Death from noncardiovascular causes was higher with colchicine (0.7 against 0.5 events per 100 person-years; hazard ratio 1.51, 95% CI 0.99 to 2.31). - Category: Effect - Evidence stage: Interventional - Certainty: Certainty not assessed - Applies to: Recipient: Adult; Population: Patients with chronic coronary disease; 5522 were randomised (abstract). The abstract does not give an age range. The trial is registered with the Australian New Zealand Clinical Trials Registry, which was not read.; Care setting: Not stated in the source (abstract only); Geography: Not stated in the source (abstract only); Life stage: Adult patients; no age range is stated in the abstract; Follow-up: Median follow-up 28.6 months (abstract). - Limitations: One randomised, double-blind trial; the abstract names the National Health Medical Research Council of Australia and others as funders. The higher rate of noncardiovascular death is reported as given and its interval includes 1. This record covers LoDoCo2 only. A separate trial of colchicine after a recent heart attack is registered as COLCOT (NCT02551094); this atlas records its registry entry and not its results. Abstract only. - Last checked: 2026-10-14 - Sources: 1. Supports: Colchicine in Patients with Chronic Coronary Disease (Publication, edition PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.) Locator: Abstract, RESULTS, sentence 1: "A total of 5522 patients underwent randomization; 2762 were assigned to the colchicine group and 2760 to the placebo group.". Retrieved 2026-10-14T18:18:41Z. Source state: Current. Snapshot hash: ddd2ae03d4ef00e0ec60f3605e8bbcff12e505f23739010ac34d3a85292c96e6. How it applies: Abstract of the paper from PubMed; the full text was not read. 2. Supports: Colchicine in Patients with Chronic Coronary Disease (Publication, edition PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.) Locator: Abstract, METHODS, sentence 1: "In a randomized, controlled, double-blind trial, we assigned patients with chronic coronary disease to receive 0.5 mg of colchicine once daily or matching placebo.". Retrieved 2026-10-14T18:18:41Z. Source state: Current. Snapshot hash: ddd2ae03d4ef00e0ec60f3605e8bbcff12e505f23739010ac34d3a85292c96e6. How it applies: Dose and comparator. 3. Supports: Colchicine in Patients with Chronic Coronary Disease (Publication, edition PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.) Locator: Abstract, METHODS, sentence 2: "The primary end point was a composite of cardiovascular death, spontaneous (nonprocedural) myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization.". Retrieved 2026-10-14T18:18:41Z. Source state: Current. Snapshot hash: ddd2ae03d4ef00e0ec60f3605e8bbcff12e505f23739010ac34d3a85292c96e6. How it applies: Primary end point. 4. Supports: Colchicine in Patients with Chronic Coronary Disease (Publication, edition PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.) Locator: Abstract, METHODS, sentence 3: "The key secondary end point was a composite of cardiovascular death, spontaneous myocardial infarction, or ischemic stroke.". Retrieved 2026-10-14T18:18:41Z. Source state: Current. Snapshot hash: ddd2ae03d4ef00e0ec60f3605e8bbcff12e505f23739010ac34d3a85292c96e6. How it applies: Key secondary end point. 5. Supports: Colchicine in Patients with Chronic Coronary Disease (Publication, edition PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.) Locator: Abstract, RESULTS, sentence 2: "The median duration of follow-up was 28.6 months.". Retrieved 2026-10-14T18:18:41Z. Source state: Current. Snapshot hash: ddd2ae03d4ef00e0ec60f3605e8bbcff12e505f23739010ac34d3a85292c96e6. How it applies: Median follow-up. 6. Supports: Colchicine in Patients with Chronic Coronary Disease (Publication, edition PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.) Locator: Abstract, RESULTS, sentence 3, fragment 1 of 2: "A primary end-point event occurred in 187 patients (6.8%) in the colchicine group and in 264 patients (9.6%) in the placebo group (incidence,". Retrieved 2026-10-14T18:18:41Z. Source state: Current. Snapshot hash: ddd2ae03d4ef00e0ec60f3605e8bbcff12e505f23739010ac34d3a85292c96e6. How it applies: Primary end point counts. 7. Supports: Colchicine in Patients with Chronic Coronary Disease (Publication, edition PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.) Locator: Abstract, RESULTS, sentence 3, fragment 2 of 2: "2.5 vs. 3.6 events per 100 person-years; hazard ratio, 0.69; 95% confidence interval \[CI\], 0.57 to 0.83; P<0.001).". Retrieved 2026-10-14T18:18:41Z. Source state: Current. Snapshot hash: ddd2ae03d4ef00e0ec60f3605e8bbcff12e505f23739010ac34d3a85292c96e6. How it applies: Primary end point rates and hazard ratio. 8. Supports: Colchicine in Patients with Chronic Coronary Disease (Publication, edition PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.) Locator: Abstract, RESULTS, sentence 4, fragment 1 of 2: "A key secondary end-point event occurred in 115 patients (4.2%) in the colchicine group and in 157 patients (5.7%) in the placebo group (incidence,". Retrieved 2026-10-14T18:18:41Z. Source state: Current. Snapshot hash: ddd2ae03d4ef00e0ec60f3605e8bbcff12e505f23739010ac34d3a85292c96e6. How it applies: Key secondary counts. 9. Supports: Colchicine in Patients with Chronic Coronary Disease (Publication, edition PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.) Locator: Abstract, RESULTS, sentence 4, fragment 2 of 2: "1.5 vs. 2.1 events per 100 person-years; hazard ratio, 0.72; 95% CI, 0.57 to 0.92; P = 0.007).". Retrieved 2026-10-14T18:18:41Z. Source state: Current. Snapshot hash: ddd2ae03d4ef00e0ec60f3605e8bbcff12e505f23739010ac34d3a85292c96e6. How it applies: Key secondary hazard ratio. 10. Supports: Colchicine in Patients with Chronic Coronary Disease (Publication, edition PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.) Locator: Abstract, RESULTS, sentence 6, fragment 1 of 2: "The incidence of death from noncardiovascular causes was higher in the colchicine group than in the placebo group (incidence,". Retrieved 2026-10-14T18:18:41Z. Source state: Current. Snapshot hash: ddd2ae03d4ef00e0ec60f3605e8bbcff12e505f23739010ac34d3a85292c96e6. How it applies: Noncardiovascular death, rates. 11. Supports: Colchicine in Patients with Chronic Coronary Disease (Publication, edition PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.) Locator: Abstract, RESULTS, sentence 6, fragment 2 of 2: "0.7 vs. 0.5 events per 100 person-years; hazard ratio, 1.51; 95% CI, 0.99 to 2.31).". Retrieved 2026-10-14T18:18:41Z. Source state: Current. Snapshot hash: ddd2ae03d4ef00e0ec60f3605e8bbcff12e505f23739010ac34d3a85292c96e6. How it applies: Noncardiovascular death, hazard ratio. 12. Background: Colchicine in Patients with Chronic Coronary Disease (Publication, edition PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.) Locator: Abstract, BACKGROUND, sentence 1, fragment 1 of 2: "Evidence from a recent trial has shown that the antiinflammatory effects of colchicine reduce the risk of cardiovascular events in patients with recent myocardial". Retrieved 2026-10-14T18:18:41Z. Source state: Current. Snapshot hash: ddd2ae03d4ef00e0ec60f3605e8bbcff12e505f23739010ac34d3a85292c96e6. How it applies: Background: an earlier trial in recent myocardial infarction. 13. Background: Colchicine in Patients with Chronic Coronary Disease (Publication, edition PubMed record (abstract and bibliographic data) from NCBI E-utilities. The full text and the version of record were not fetched.) Locator: Abstract, CONCLUSIONS, sentence 2: "(Funded by the National Health Medical Research Council of Australia and others; LoDoCo2 Australian New Zealand Clinical Trials Registry number, ACTRN12614000093684.).". Retrieved 2026-10-14T18:18:41Z. Source state: Current. Snapshot hash: ddd2ae03d4ef00e0ec60f3605e8bbcff12e505f23739010ac34d3a85292c96e6. How it applies: Funding and registry note in the abstract. 14. Background: Colchicine Cardiovascular Outcomes Trial (COLCOT) (Registry, edition ClinicalTrials.gov API v2 record, last update posted 2020-10-19.) Locator: protocolSection.identificationModule.officialTitle: "Colchicine Cardiovascular Outcomes Trial (COLCOT)". Retrieved 2026-10-14T18:18:41Z. Source state: Current. Snapshot hash: 853218a89e798bbb4547b5b565e25641d6bb71af58d65795257862c561df8e5b. How it applies: COLCOT registry record exists; its results are not recorded here. 15. Background: Colchicine Cardiovascular Outcomes Trial (COLCOT) (Registry, edition ClinicalTrials.gov API v2 record, last update posted 2020-10-19.) Locator: protocolSection.conditionsModule.conditions\[1\]: "Myocardial Infarction". Retrieved 2026-10-14T18:18:41Z. Source state: Current. Snapshot hash: 853218a89e798bbb4547b5b565e25641d6bb71af58d65795257862c561df8e5b. How it applies: COLCOT lists myocardial infarction as a condition. ## Connected pages - Fewer events in chronic coronary disease at low dose: Coronary artery disease (`cardio:coronary-artery-disease`) [a claim, not a settled fact; see claim `cardio:claim-lodoco2-low-dose-colchicine` and its context] - Files under this front: Medicines (`cardio:front-medicines`) ## Provenance Content hash: c999d5d071e913fd0ef500f59d67550f3cf8bf494fb3ceaa324fbf7bd0419a5e Last substantive edit: 2026-10-14 Evidence last checked: 2026-10-14